Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)
A Randomised, Double-blind, Double-dummy, Parallel Group, International (Asian), Multicenter, Phase 3 Study to Assess Safety and Efficacy of AZD6140 on Top of Low Dose Acetyl Salicylic Acid (ASA) Versus Clopidogrel on Top of Low Dose ASA in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes(ACS) for Whom PCI is Planned
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Fukuoka, Japan
- Research Site
-
Gifu, Japan
- Research Site
-
Kumamoto, Japan
- Research Site
-
Oita, Japan
- Research Site
-
Saga, Japan
- Research Site
-
Wakayama, Japan
- Research Site
-
-
Aichi
-
Ichinomiya-shi, Aichi, Japan
- Research Site
-
Nagoya-shi, Aichi, Japan
- Research Site
-
Okazaki-shi, Aichi, Japan
- Research Site
-
Toyohashi-shi, Aichi, Japan
- Research Site
-
Toyota-shi, Aichi, Japan
- Research Site
-
-
Akita
-
Akita-shi, Akita, Japan
- Research Site
-
-
Chiba
-
Ichihara-shi, Chiba, Japan
- Research Site
-
Kamogawa-shi, Chiba, Japan
- Research Site
-
Kisarazu-shi, Chiba, Japan
- Research Site
-
-
Ehime
-
Matsuyama, Ehime, Japan
- Research Site
-
-
Fukui
-
Fukui-shi, Fukui, Japan
- Research Site
-
-
Fukuoka
-
Fukuoka-shi, Fukuoka, Japan
- Research Site
-
Kasuya-gun, Fukuoka, Japan
- Research Site
-
Kurume, Fukuoka, Japan
- Research Site
-
-
Gifu
-
Gifu-shi, Gifu, Japan
- Research Site
-
-
Gunma
-
Isesaki, Gunma, Japan
- Research Site
-
Maebashi, Gunma, Japan
- Research Site
-
Takasaki-shi, Gunma, Japan
- Research Site
-
-
Hiroshima
-
Kure, Hiroshima, Japan
- Research Site
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan
- Research Site
-
Sapporo-shi, Hokkaido, Japan
- Research Site
-
-
Hyogo
-
Akashi-shi, Hyogo, Japan
- Research Site
-
Amagasaki-shi, Hyogo, Japan
- Research Site
-
Kawanishi-shi, Hyogo, Japan
- Research Site
-
Kobe, Hyogo, Japan
- Research Site
-
Kobe-shi, Hyogo, Japan
- Research Site
-
Nishinomiya, Hyogo, Japan
- Research Site
-
Takarazuka-shi, Hyogo, Japan
- Research Site
-
-
Ibaragi
-
Higashiibaragi-gun, Ibaragi, Japan
- Research Site
-
Sashima-gun, Ibaragi, Japan
- Research Site
-
-
Ishikawa
-
Hakusan-shi, Ishikawa, Japan
- Research Site
-
Kanazawa, Ishikawa, Japan
- Research Site
-
Kanazawa-shi, Ishikawa, Japan
- Research Site
-
-
Kagawa
-
Sakaide-shi, Kagawa, Japan
- Research Site
-
-
Kanagawa
-
Atsugi-shi, Kanagawa, Japan
- Research Site
-
Isehara, Kanagawa, Japan
- Research Site
-
Kamakura-shi, Kanagawa, Japan
- Research Site
-
Kawasaki-shi, Kanagawa, Japan
- Research Site
-
Sagamihara-shi, Kanagawa, Japan
- Research Site
-
Yamato-shi, Kanagawa, Japan
- Research Site
-
Yokohama-shi, Kanagawa, Japan
- Research Site
-
-
Kochi
-
Nankoku-shi, Kochi, Japan
- Research Site
-
-
Kumamoto
-
Kumamoto-shi, Kumamoto, Japan
- Research Site
-
Yatsushiro-city, Kumamoto, Japan
- Research Site
-
-
Kyoto
-
Kyoto-shi, Kyoto, Japan
- Research Site
-
-
Miyagi
-
Sendai-shi, Miyagi, Japan
- Research Site
-
-
Nagano
-
Azumino-shi, Nagano, Japan
- Research Site
-
Ueda-shi, Nagano, Japan
- Research Site
-
-
Nagasaki
-
Nagasaki-shi, Nagasaki, Japan
- Research Site
-
-
Okayama
-
Kurashiki, Okayama, Japan
- Research Site
-
Okayama-shi, Okayama, Japan
- Research Site
-
-
Osaka
-
Hirakata, Osaka, Japan
- Research Site
-
Kawachinagano-shi, Osaka, Japan
- Research Site
-
Osaka-shi, Osaka, Japan
- Research Site
-
Sakai-shi, Osaka, Japan
- Research Site
-
-
Saga
-
Saga-shi, Saga, Japan
- Research Site
-
-
Saitama
-
Ageo-shi, Saitama, Japan
- Research Site
-
Hidaka, Saitama, Japan
- Research Site
-
Sayama-shi, Saitama, Japan
- Research Site
-
-
Shiga
-
Kusatsu-shi, Shiga, Japan
- Research Site
-
Moriyama, Shiga, Japan
- Research Site
-
-
Shimane
-
Matsue, Shimane, Japan
- Research Site
-
-
Shizuoka
-
Hamamatsu-shi, Shizuoka, Japan
- Research Site
-
Izunokuni, Shizuoka, Japan
- Research Site
-
Shimada-shi, Shizuoka, Japan
- Research Site
-
Sunto-gun, Shizuoka, Japan
- Research Site
-
-
Tokushima
-
Komatsushima-shi, Tokushima, Japan
- Research Site
-
Tokushima-shi, Tokushima, Japan
- Research Site
-
-
Tokyo
-
Adachi-ku, Tokyo, Japan
- Research Site
-
Bunkyo, Tokyo, Japan
- Research Site
-
Bunkyo-ku, Tokyo, Japan
- Research Site
-
Chiyoda-ku, Tokyo, Japan
- Research Site
-
Itabashi-ku, Tokyo, Japan
- Research Site
-
Meguro, Tokyo, Japan
- Research Site
-
Ome-shi, Tokyo, Japan
- Research Site
-
Shinagawa-ku, Tokyo, Japan
- Research Site
-
Shinjuku, Tokyo, Japan
- Research Site
-
Suginami-ku, Tokyo, Japan
- Research Site
-
-
Wakayama
-
Tanabe-shi, Wakayama, Japan
- Research Site
-
-
Yamanashi
-
Chuo-shi, Yamanashi, Japan
- Research Site
-
-
-
-
-
Daejeon, Korea, Republic of
- Research Site
-
Incheon, Korea, Republic of
- Research Site
-
Seoul, Korea, Republic of
- Research Site
-
-
Chungcheongnam-do
-
Cheonan, Chungcheongnam-do, Korea, Republic of
- Research Site
-
-
-
-
-
Taichung, Taiwan
- Research Site
-
Taipei, Taiwan
- Research Site
-
-
Kaohsiung
-
Niao-song-shiang, Kaohsiung, Taiwan
- Research Site
-
-
Taoyuan Hsien
-
Kweishan Shiang, Taoyuan Hsien, Taiwan
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of signed informed consent
- Index event of non-ST or ST segment elevation ACS
Exclusion Criteria:
- Index event is an acute complication of percutaneous coronary intervention
- Patient has undergone Percutaneous Coronary Intervention (PCI) after the index event before the first dose of study treatment
- Oral anticoagulation therapy that cannot be stopped
- The conditions associated with increased risk of bradycardiac events
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: 1
Ticagrelor (AZD6140)
|
90 mg, oral dose twice daily
Other Names:
Low Dose ASA
|
|
ACTIVE_COMPARATOR: 2
Clopidogrel
|
Low Dose ASA
75 mg, oral dose once daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Major Bleeding
Time Frame: Ongoing up to12 months
|
Time to first occurrence of any major bleeding event (adjudicated by an independent Clinical Endpoint Committee (ICEC)).
1-year event rate (%) estimated via Kaplan-Meier method.
|
Ongoing up to12 months
|
|
Major Adverse Cardiac Events (MACE)
Time Frame: Ongoing up to 12 months
|
Time to first occurrence of any event from the composite of death from vascular causes, Myocardial Infarction (MI) and stroke (adjudicated by an ICEC).
1-year event rate (%) estimated via Kaplan-Meier method.
|
Ongoing up to 12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Major and Minor Bleeding
Time Frame: Ongoing up to12 months
|
Time to first occurrence of any major or minor bleeding event (adjudicated by an independent Clinical Endpoint Committee (ICEC)).
1-year event rate (%) estimated via Kaplan-Meier method.
|
Ongoing up to12 months
|
|
Composite of All-cause Mortality, MI or Stroke
Time Frame: Ongoing up to 12 months
|
Time to first occurrence of any event from the composite of death from any causes, Myocardial Infarction (MI) and stroke (adjudicated by an ICEC).
1-year event rate (%) estimated via Kaplan-Meier method.
|
Ongoing up to 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Judith Hsia, MD, AstraZeneca
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Disease
- Syndrome
- Acute Coronary Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Aspirin
- Ticagrelor
- Clopidogrel
Other Study ID Numbers
Other Study ID Numbers
- D5130C00027
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.